Pzena Investment Management LLC Trims Stock Position in Bristol Myers Squibb Company $BMY

Pzena Investment Management LLC decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.7% in the 1st quarter, Holdings Channel reports. The institutional investor owned 17,095,731 shares of the biopharmaceutical company’s stock after selling 847,772 shares during the period. Bristol Myers Squibb accounts for about 3.4% of Pzena Investment Management LLC’s portfolio, making the stock its 6th biggest position. Pzena Investment Management LLC’s holdings in Bristol Myers Squibb were worth $1,036,856,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. lifted its position in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter worth about $25,000. Bayban acquired a new position in Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the fourth quarter worth $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb is continuing its collaboration with Arcus Biosciences on a kidney cancer trial, adding Arcus’s investigational drug casdatifan to Bristol Myers’ Phase 1/2 ROSETTA RCC-208 study. The update reinforces BMY’s pipeline activity in oncology, which could support long-term growth if the combination shows promise. Article Title
• Positive Sentiment: Several articles highlighted Bristol Myers Squibb as a value stock and a “trending” name, which can attract investor interest and reinforce the view that BMY may be attractive at its current valuation relative to peers. Article Title
• Positive Sentiment: Unusually heavy call-option activity suggests some traders are positioning for a rebound or a near-term move higher in Bristol Myers Squibb shares. Article Title
• Neutral Sentiment: Brisbane Myers Squibb was added to Russell 1000 Value Defensive and Defensive indexes while being removed from growth-oriented benchmarks. This mainly reflects a style reclassification rather than a direct business change, though it may influence fund flows and how investors view the stock. Article Title
• Negative Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for BMY to $6.31 from $6.32, a small cut that nevertheless signals modestly softer expectations for earnings growth. Article Title
• Negative Sentiment: Concerns about proposed Medicare drug-price negotiation changes remain a headwind for Bristol Myers Squibb, since policy pressure on drug pricing could affect future revenue and margins. Article Title

Bristol Myers Squibb Stock Down 2.0%

NYSE:BMY opened at $56.46 on Thursday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a market cap of $115.30 billion, a PE ratio of 15.86, a P/E/G ratio of 0.16 and a beta of 0.23. The firm’s 50 day simple moving average is $56.95 and its 200 day simple moving average is $57.44.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Wall Street Analyst Weigh In

BMY has been the subject of a number of analyst reports. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. HSBC raised their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Bank of America dropped their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.